Imeryz N, Yeen B, Bozkurt A, Cokun T, Villanueva-Penacarrillo ML, Ulusoy NB
Many patients expect immediate weight loss with semaglutide , but the process is more gradual
6 Moreover, GIPR signaling blocks emesis and attenuates other negative side effects of GLP-1 receptor (GLP-1R) activation
Zepbound is administered as a once-weekly subcutaneous injection, with doses starting at 2.5 mg and increasing in 2.5 mg increments after at least 4 weeks, up to a maximum of 15 mg depending on individual tolerance and treatment response
For patients exploring weight management, GLP-1 peptide therapies (such as compounded semaglutide or tirzepatide from PlexusDx) have substantially more robust clinical evidence supporting appetite regulation and metabolic improvement
A consultation with your healthcare provider can help you identify the issue and make necessary adjustments